Close Menu

    Get the latest news around the globe

    Editor's Pick

    World’s ocean surface temperature hits all-time high; Report

    Breakthrough cervical cancer treatment cuts death risk by 40%

    UK approves Microsoft’s deal to buy Call of Duty maker Activision

    Facebook X (Twitter) Instagram
    Facebook X (Twitter) LinkedIn Instagram
    Britain HeraldBritain Herald
    Subscribe
    • Home
    • World Roundup
    • Business
    • Tech World
    • Entertainment & Events
    • Curious
    • More…
      • Spotlight
      • Knowledge
      • Lifestyle
      • Awareness
      • Women World
      • Sports
      • Travel
      • Notable
      • Contact Us
    Britain HeraldBritain Herald
    Home » Alzheimer’s drug Lecanemab hailed as a landmark breakthrough
    Home News

    Alzheimer’s drug Lecanemab hailed as a landmark breakthrough

    Lecanemab is a synthetic antibody, which is similar to those the body produces to fight germs or viruses, that stimulates the immune system to remove amyloid from the brain.
    News DeskBy News DeskNovember 30, 2022
    Facebook Twitter LinkedIn WhatsApp
    Eli Lilly Experimental Alzheimer's Drug
    Rep.Image: Unsplash

    Massachusetts: Lecanemab, the drug which is designed to target and clear amyloid, has become the first drug to slow the destruction of the brain in Alzheimer’s disease.

    The new drug has been hailed as a major breakthrough in Alzheimer’s treatment, soon after it was found to reduce memory loss in patients in the early stages of the disease.

    Lecanemab is a synthetic antibody, which is similar to those the body produces to fight germs or viruses, that stimulates the immune system to remove amyloid from the brain.

    According to Professor John Hardy, group leader at the UK Dementia Research Institute at University College London, this trial is an important first step, and it represents the “beginning of the end.”

    Alzheimer's Drug Lecanemab _ Image
    Image: The New England Journal of Medicine @ Facebook

    The first step is the hardest, and we now know exactly what we need to do to develop effective drugs. It’s exciting to think that future work will build on this, and we will soon have life-changing treatments to tackle this disease.

    Prof. John Hardy remarked.

    The results of the phase three clinical study have been released by Eisai, a Tokyo-based pharmaceutical company that collaborates with the US biotech company Biogen to manufacture Lecanemab. In September 2022, Eisai released the preliminary findings of a study including 1,795 participants with early-stage Alzheimer’s disease.

    The complete study has been published in The New England Journal of Medicine, with experts claiming it as long-awaited evidence that Alzheimer’s disease can be treated.

    Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months.

    Alzheimer's Drug Lecanemab _ Rep.Image
    Rep.Image: Unsplash

    Prof. Bart De Strooper, Molecular Biologist at the Vlaams Instituut voor Biotechnologie, stated that, “the overall conclusion is extremely positive. This trial proves that Alzheimer’s disease can be treated.”

    Currently, certain medications are given to Alzheimer’s patients to help manage their symptoms, but none change the course of the illness.

    TECH WORLD: Apple threatens to remove Twitter from App Store; Elon Musk

    STAR OF SECTOR 2025
    Alzheimer's Drug Lecanemab Bart De Strooper on Lecanemab Drug for Alzheimer's Disease Eisai on Lecanemab Drug John Hardy on Lecanemab The New England Journal of Medicine The New England Journal of Medicine Study on Lecanemab UK Dementia Research Institute UK Dementia Research Institute on Lecanemab
    Share. Facebook Twitter LinkedIn WhatsApp
    Avatar
    News Desk

    The news/article published above has been sourced, compiled, and corroborated by a member of the Britain Herald News Desk Team. If you have any queries or complaints about the published material, please get in touch with us at BritainHerald@Gmail.Com

    Newly Updated

    Mars Mission: Musk bets on 50% chance for 2026 launch

    May 30, 2025

    The AI eye: Spotting prostate cancer patients who truly need the cure

    May 30, 2025

    China protests US plan to aggressively revoke student visas

    May 29, 2025
    STAR OF SECTOR 2025

    Business

    Nvidia reports rising revenue as global AI demand surges

    Business May 29, 2025

    United States: Nvidia has reported a significant boost in its first-quarter earnings, with revenue surging…

    Volvo cars to cut 3,000 jobs in major restructuring effort

    May 27, 2025

    Trump demands US-made iPhones; Warns of 25% tariff

    May 24, 2025

    Nike to raise prices on select items citing seasonal planning

    May 22, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • LinkedIn
    • Instagram

    Curious

    Massive ice calving at Perito Moreno Glacier sparks concern

    May 16, 2025

    Glowing Spiral appears in night sky; Linked to SpaceX Falcon 9 Rocket

    March 25, 2025

    Once dubbed ‘Ugliest’; Blobfish triumphs as NZ ‘Fish of the Year’

    March 19, 2025

    Giant Iceberg A23a runs aground near South Georgia; Easing wildlife fears

    March 5, 2025

    Get the latest news around the globe

    Knowledge

    Clownfish shrinks to survive marine heatwaves, study reveals

    Knowledge May 22, 2025

    England: Clownfish, famously known from the film Finding Nemo, are shrinking in size to survive…

    Kashmir conflict: History of disputes, wars, and unresolved tensions

    May 9, 2025

    Snakebite survivor’s blood sparks universal antivenom discovery

    May 3, 2025

    ESA’s Biomass satellite set for launch to map forest carbon

    April 29, 2025
    18-EA-387-TryEngineeringSummerInst_BannerAd_300x250_Robot
    About Us
    About Us

    Britain Herald is a global news brand that plays a significant role in educating and informing the masses with informative content, the latest updates, and current affairs across the World.

    Operated and Managed by WellMade Network, the portal is a sister concern of GCC Business News and Emirati Times. For inquiries about Media Partnerships, Investment and other opportunities in line with our Editorial Policy, please contact us at;

    Email Us: News@BritainHerald.com
    Whatsapp: +971 5060 12456

    We Have

    Mars Mission: Musk bets on 50% chance for 2026 launch

    May 30, 2025

    The AI eye: Spotting prostate cancer patients who truly need the cure

    May 30, 2025

    China protests US plan to aggressively revoke student visas

    May 29, 2025

    Devastating glacier collapse destroys Swiss village of Blatten

    May 29, 2025
    Facebook X (Twitter) LinkedIn Instagram
    • Home
    • Business
    • Tech World
    • Awareness
    • Contact Us
    Privacy & Cookies Policy | Terms & Conditions
    © 2002 BritainHerald.com, An Initiative by WellMade Network

    Type above and press Enter to search. Press Esc to cancel.